Predictors of two-year survival in patients receiving chemotherapy for metastatic pancreatic ductal adenocarcinoma (mPDAC): A single-center retrospective cohort study.

666 Background: Median survival in patients with mPDAC is typically between 6 and 11 months, and survival of more than two years is uncommon. Given the high mortality of mPDAC, identifying prognostically favorable characteristics could improve risk stratification and better inform early goals of care discussions. We conducted an exploratory analysis to identify characteristics associated with survival of ≥2 years among patients with mPDAC. Methods: We conducted a retrospective study of patients receiving chemotherapy for mPDAC within a single health system from 2015-2024. We abstracted patient demographic and clinical characteristics, baseline laboratory values, and overall survival (OS, defined as days between the first chemotherapy administration for mPDAC and date of death). We compared the distribution of demographic and clinical characteristics and baseline laboratory values across cohorts of ≥2 vs.